Literature DB >> 18848348

Outcome of patients with bladder cancer with pN+ disease after preoperative chemotherapy and radical cystectomy.

Wassim Kassouf1, Piyush K Agarwal, H Barton Grossman, Dan Leibovici, Mark F Munsell, Arlene Siefker-Radtke, Louis L Pisters, David A Swanson, Colin P N Dinney, Ashish M Kamat.   

Abstract

OBJECTIVES: Persistent nodal disease in the surgical specimen (pN+) after preoperative chemotherapy for urothelial carcinoma is associated with a poor prognosis. To improve our understanding regarding the outcomes of such patients, we performed a retrospective review of our experience.
METHODS: From 1993 to 2003, 857 patients underwent radical cystectomy for urothelial carcinoma of the bladder, and 150 were found to have pN+ disease. Of these 150 patients, 37 had pN+ disease despite preoperative chemotherapy and formed the basis of this report. The survival data were analyzed using the Kaplan-Meier method and Cox regression analysis.
RESULTS: The median patient age was 66 years (range 39-85), and the median follow-up was 50 months (range 13.0-58.7). The clinical stage at the initiation of preoperative chemotherapy was cT2 with lymphovascular invasion in 7, cT3b in 6, cT4a in 4, cT4b in 2, and cN+ in 18. The 2-year overall, disease-specific, and recurrence-free survival rate was 20%, 29.2%, and 13.5%, respectively. Of the 37 patients, 11 (30%) received adjuvant chemotherapy after surgery, most (73%) were platinum-based regimens. On Kaplan-Meier analysis, adjuvant chemotherapy was associated with improved recurrence-free and disease-specific survival. On multivariate analysis, surgical margin status, sex, and histologic type were significantly associated with overall survival, and the histologic type and use of adjuvant chemotherapy were significantly associated with recurrence-free survival.
CONCLUSIONS: Patients with persistent nodal disease despite preoperative chemotherapy have a poor prognosis. A cohort of such patients might do well with adjuvant chemotherapy. The lymph node density and pT category were not prognostic in patients with nodal metastasis after preoperative chemotherapy.

Entities:  

Mesh:

Year:  2008        PMID: 18848348      PMCID: PMC2674246          DOI: 10.1016/j.urology.2008.07.035

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  14 in total

Review 1.  Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis.

Authors:  Eric Winquist; Tricia S Kirchner; Roanne Segal; Joseph Chin; Himu Lukka
Journal:  J Urol       Date:  2004-02       Impact factor: 7.450

2.  Evaluation of the relevance of lymph node density in a contemporary series of patients undergoing radical cystectomy.

Authors:  Wassim Kassouf; Dan Leibovici; Mark F Munsell; Colin P Dinney; H Barton Grossman; Ashish M Kamat
Journal:  J Urol       Date:  2006-07       Impact factor: 7.450

3.  Adjuvant chemotherapy in advanced bladder cancer. Italian Uro-Oncologic Cooperative Group.

Authors:  A V Bono; C Benvenuti; L Reali; E Pozzi; A Gibba; S Cosciani-Cunico; U Comuzzi; G Anselmo
Journal:  Prog Clin Biol Res       Date:  1989

4.  Advanced bladder cancer (stages pT3b, pT4a, pN1 and pN2): improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy. Results of a controlled prospective study.

Authors:  M Stöckle; W Meyenburg; S Wellek; G Voges; U Gertenbach; J W Thüroff; C Huber; R Hohenfellner
Journal:  J Urol       Date:  1992-08       Impact factor: 7.450

5.  Surgical factors influence bladder cancer outcomes: a cooperative group report.

Authors:  Harry W Herr; James R Faulkner; H Barton Grossman; Ronald B Natale; Ralph deVere White; Michael F Sarosdy; E David Crawford
Journal:  J Clin Oncol       Date:  2004-06-15       Impact factor: 44.544

6.  Nodal involvement in bladder cancer cases treated with radical cystectomy: incidence and prognosis.

Authors:  Mohamed Abdel-Latif; Hassan Abol-Enein; Mahmoud El-Baz; Mohamed A Ghoneim
Journal:  J Urol       Date:  2004-07       Impact factor: 7.450

7.  Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer.

Authors:  H Barton Grossman; Ronald B Natale; Catherine M Tangen; V O Speights; Nicholas J Vogelzang; Donald L Trump; Ralph W deVere White; Michael F Sarosdy; David P Wood; Derek Raghavan; E David Crawford
Journal:  N Engl J Med       Date:  2003-08-28       Impact factor: 91.245

8.  A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer.

Authors:  F Freiha; J Reese; F M Torti
Journal:  J Urol       Date:  1996-02       Impact factor: 7.450

9.  The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial.

Authors:  D G Skinner; J R Daniels; C A Russell; G Lieskovsky; S D Boyd; P Nichols; W Kern; J Sakamoto; M Krailo; S Groshen
Journal:  J Urol       Date:  1991-03       Impact factor: 7.450

10.  Pelvic lymph node dissection can be curative in patients with node positive bladder cancer.

Authors:  J Vieweg; J E Gschwend; H W Herr; W R Fair
Journal:  J Urol       Date:  1999-02       Impact factor: 7.450

View more
  17 in total

1.  Editorial comment.

Authors:  Michele Pavone-Macaluso
Journal:  Int Urol Nephrol       Date:  2009-12       Impact factor: 2.370

2.  The Role of Surgery in Metastatic Bladder Cancer: A Systematic Review.

Authors:  Mohammad Abufaraj; Guido Dalbagni; Siamak Daneshmand; Simon Horenblas; Ashish M Kamat; Ryu Kanzaki; Alexandre R Zlotta; Shahrokh F Shariat
Journal:  Eur Urol       Date:  2017-11-07       Impact factor: 20.096

Review 3.  Systemic, perioperative management of muscle-invasive bladder cancer and future horizons.

Authors:  Samuel A Funt; Jonathan E Rosenberg
Journal:  Nat Rev Clin Oncol       Date:  2016-11-22       Impact factor: 66.675

Review 4.  Overview of Current and Future Adjuvant Therapy for Muscle-Invasive Urothelial Carcinoma.

Authors:  Rosa Nadal; Andrea B Apolo
Journal:  Curr Treat Options Oncol       Date:  2018-05-28

5.  Clinical response to induction chemotherapy predicts improved survival outcome in urothelial carcinoma with clinical lymph nodal metastasis treated by consolidative surgery.

Authors:  Shinji Urakami; Takeshi Yuasa; Shinya Yamamoto; Mizuaki Sakura; Hajime Tanaka; Tatsuro Hayashi; Sho Uehara; Yasushi Inoue; Yasuhisa Fujii; Hitoshi Masuda; Iwao Fukui; Junji Yonese
Journal:  Int J Clin Oncol       Date:  2015-05-08       Impact factor: 3.402

Review 6.  Role and extent of lymphadenectomy during radical cystectomy for invasive bladder cancer.

Authors:  Robert Svatek; Pascal Zehnder
Journal:  Curr Urol Rep       Date:  2012-04       Impact factor: 3.092

7.  Histologic variants of urothelial bladder cancer and nonurothelial histology in bladder cancer.

Authors:  Venu Chalasani; Joseph L Chin; Jonathan I Izawa
Journal:  Can Urol Assoc J       Date:  2009-12       Impact factor: 1.862

Review 8.  Practical use of perioperative chemotherapy for muscle-invasive bladder cancer: summary of session at the Society of Urologic Oncology annual meeting.

Authors:  Andrea B Apolo; Herbert Barton Grossman; Dean Bajorin; Gary Steinberg; Ashish M Kamat
Journal:  Urol Oncol       Date:  2012 Nov-Dec       Impact factor: 3.498

Review 9.  Management of Clinically Regional Node-Positive Urothelial Carcinoma of the Bladder.

Authors:  Chanan Reitblat; Joaquim Bellmunt; Boris Gershman
Journal:  Curr Oncol Rep       Date:  2021-02-09       Impact factor: 5.075

10.  miR-101 suppresses vascular endothelial growth factor C that inhibits migration and invasion and enhances cisplatin chemosensitivity of bladder cancer cells.

Authors:  Ye Lei; Bin Li; Shiyu Tong; Lin Qi; Xiheng Hu; Yunbo Cui; Zengbo Li; Wei He; Xiongbing Zu; Zhi Wang; Minfeng Chen
Journal:  PLoS One       Date:  2015-02-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.